Powder: -20°C for 3 years | In solvent: -80°C for 1 year
R1530 是一种多激酶抑制剂,具有抗肿瘤和抗血管生成活性。它是具有口服活性的有丝分裂/血管生成高效双重作用抑制剂, 抑制 VGFR2、FGFR1作用的 IC50分别为 10 nM 和 28 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 478 | 现货 | ||
2 mg | ¥ 697 | 现货 | ||
5 mg | ¥ 1,160 | 现货 | ||
10 mg | ¥ 1,730 | 现货 | ||
25 mg | ¥ 3,490 | 现货 | ||
50 mg | ¥ 4,970 | 现货 | ||
100 mg | ¥ 7,230 | 现货 |
产品描述 | R1530 is a multikinase inhibitor with antineoplastic and antiangiogenesis activities. |
靶点活性 | VGFR2:10 nM, FGFR1:28 nM |
体外活性 | R1530 inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as VEGFR-1/2/3, PDGFR, Flt-3, and FGFR-1/2. In the presence of R1530, polyploid cancer cells underwent apoptosis or became senescent which translated into potent in vitro and in vivo efficacy. Normal proliferating cells were resistant to R1530-induced polyploidy. Mitotic checkpoint kinase BubR1 was found downregulated during R1530-induced exit from mitosis, a likely consequence of PLK4 inhibition [1]. R1530 strongly inhibited human tumor cell proliferation. Growth factor-driven proliferation of endothelial and fibroblast cells was also inhibited [2]. |
体内活性 | Showing significant tumor growth inhibition in a lung cancer xenograft model, R1530 was administered at doses ranging from once daily, weekly and twice weekly (3.125-50 mg/kg qd, 100 mg/kg qw, 100 mg/kg kg biw). Tumor regression occurred in all models treated with the maximum tolerated daily dose (50 mg/kg). Doses of 25 and 50 mg/kg qd resulted in biologically significant increases in survival in all models tested. After oral administration to nude mice, R1530 showed good tissue permeability. Exposure was dose-dependent, up to 100 mg/kg when administered orally[2]. |
别名 | R-1530, R 1530 |
分子量 | 356.78 |
分子式 | C18H14ClFN4O |
CAS No. | 882531-87-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (14.01 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8028 mL | 14.0142 mL | 28.0285 mL | 70.0712 mL |
5 mM | 0.5606 mL | 2.8028 mL | 5.6057 mL | 14.0142 mL | |
10 mM | 0.2803 mL | 1.4014 mL | 2.8028 mL | 7.0071 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
R1530 882531-87-5 Angiogenesis Tyrosine Kinase/Adaptors FLT FGFR VEGFR PDGFR antitumor Inhibitor Fibroblast growth factor receptor mitosis angiogenesis R-1530 R 1530 antiproliferative Apoptosis inhibit mitotic Vascular endothelial growth factor receptor inhibitor